中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1797-1804

Chronic hepatitis B comorbid with nonalcoholic fatty liver disease: Contemporary insights and controversies

DOI: 10.3969/j.issn.1001-5256.2023.08.005

  • Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Research funding:

National Natural Science Foundation of China (81871242)

More Information
  • Corresponding author: LI Jun, dr-lijun@vip.sina.com (ORCID: 0000-0002-1961-7188)
  • Received Date: 2023-05-08
  • Accepted Date: 2023-06-21
  • Published Date: 2023-08-20
    Abstract
  • In China, a substantial number of patients suffer from chronic hepatitis B (CHB), and the incidence rate of nonalcoholic fatty liver disease (NAFLD) has been increasing in recent years, with a tendency of increase in the prevalence rate of CHB and NAFLD. Since the outcome of CHB or NAFLD is liver cirrhosis and hepatocellular carcinoma (HCC), the comorbidity of these two diseases has attracted wide attention and extensive research. Currently, there are still controversies over the risk of HCC due to CHB comorbid with NAFLD, all-cause mortality rate, and the efficacy of antiviral therapy, and the mechanism of interaction remains unknown. Therefore, this article briefly reviews CHB comorbid with NAFLD and discusses the association between the two diseases, in order to provide a reference for clinical management.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    HUANG DQ, SINGAL AG, KONO Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer[J]. Cell Metab, 2022, 34(7): 969-977. e2. DOI: 10.1016/j.cmet.2022.05.003.
    [3]
    YANG RX, FAN JG. Clinical research advances in chronic hepatitis B complicated by fatty liver disease[J]. Chin J Hepatol, 2018, 26(1): 73-76. DOI: 10.3760/cma.j.issn.1007-3418.2018.01.017.

    杨蕊旭, 范建高. 慢性乙型肝炎合并脂肪肝临床研究进展[J]. 中华肝脏病杂志, 2018, 26(1): 73-76. DOI: 10.3760/cma.j.issn.1007-3418.2018.01.017.
    [4]
    YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia[J]. Liver Int, 2022, 42(9): 1981-1990. DOI: 10.1111/liv.15252.
    [5]
    ZHANG RN, PAN Q, ZHANG Z, et al. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response[J]. Hepat Mon, 2015, 15(5): e27909. DOI: 10.5812/hepatmon.15(5)2015.27909.
    [6]
    HU D, WANG H, WANG H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model[J]. Hepatol Int, 2018, 12(5): 438-446. DOI: 10.1007/s12072-018-9877-7.
    [7]
    KHANMOHAMMADI S, KUCHAY MS. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease[J]. Pharmacol Res, 2022, 185: 106507. DOI: 10.1016/j.phrs.2022.106507.
    [8]
    TANG Y, BIAN Z, ZHAO L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease[J]. Clin Exp Immunol, 2011, 166(2): 281-290. DOI: 10.1111/j.1365-2249.2011.04471.x.
    [9]
    LI HJ, KANG FB, LI BS, et al. Interleukin-21 inhibits HBV replication in vitro[J]. Antivir Ther, 2015, 20(6): 583-590. DOI: 10.3851/IMP2950.
    [10]
    CHEN HM, LIU HL, YANG YC, et al. Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure[J]. Exp Ther Med, 2014, 7(4): 1013-1019. DOI: 10.3892/etm.2014.1533.
    [11]
    SHLOMAI A, PARAN N, SHAUL Y. PGC-1alpha controls hepatitis B virus through nutritional signals[J]. Proc Natl Acad Sci U S A, 2006, 103(43): 16003-16008. DOI: 10.1073/pnas.0607837103.
    [12]
    LI J, YANG HI, YEH ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224(2): 294-302. DOI: 10.1093/infdis/jiaa739.
    [13]
    CHU CM, LIN DY, LIAW YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?[J]. Int J Obes (Lond), 2007, 31(5): 871-875. DOI: 10.1038/sj.ijo.0803479.
    [14]
    LI J, LE AK, CHAUNG KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients[J]. Liver Int, 2020, 40(5): 1052-1061. DOI: 10.1111/liv.14415.
    [15]
    TAI DI, LIN SM, SHEEN IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time[J]. Hepatology, 2009, 49(6): 1859-1867. DOI: 10.1002/hep.22878.
    [16]
    CHANG JW, LEE JS, LEE HW, et al. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1545-1553. DOI: 10.1111/jvh.13594.
    [17]
    MAO X, CHEUNG KS, PENG C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2023, 77(5): 1735-1745. DOI: 10.1002/hep.32792.
    [18]
    SHI YX, HUANG CJ, YANG ZG. Impact of hepatitis B virus infection on hepatic metabolic signaling pathway[J]. World J Gastroenterol, 2016, 22(36): 8161-8167. DOI: 10.3748/wjg.v22.i36.8161.
    [19]
    HAJJOU M, NOREL R, CARVER R, et al. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV[J]. J Med Virol, 2005, 77(1): 57-65. DOI: 10.1002/jmv.20427.
    [20]
    WU YL, PENG XE, ZHU YB, et al. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein[J]. J Virol, 2016, 90(4): 1729-1740. DOI: 10.1128/JVI.02604-15.
    [21]
    PAN Q, CHEN MM, ZHANG RN, et al. PNPLA3 rs1010023 predisposes chronic hepatitis B to hepatic steatosis but improves insulin resistance and glucose metabolism[J]. J Diabetes Res, 2017, 2017: 4740124. DOI: 10.1155/2017/4740124.
    [22]
    LI JZ, YE LH, WANG DH, et al. The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD[J]. Virus Res, 2021, 298: 198405. DOI: 10.1016/j.virusres.2021.198405.
    [23]
    LIU PT, HWANG AC, CHEN JD. Combined effects of hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia[J]. Metabolism, 2013, 62(2): 220-225. DOI: 10.1016/j.metabol.2012.07.022.
    [24]
    HUANG CY, LU CW, LIU YL, et al. Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach[J]. Obesity (Silver Spring), 2016, 24(2): 483-489. DOI: 10.1002/oby.21333.
    [25]
    CHEN JY, WANG JH, LIN CY, et al. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently[J]. J Gastroenterol Hepatol, 2010, 25(11): 1763-1768. DOI: 10.1111/j.1440-1746.2010.06300.x.
    [26]
    HSU CS, LIU CH, WANG CC, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J]. J Viral Hepat, 2012, 19(2): e48-e57. DOI: 10.1111/j.1365-2893.2011.01535.x.
    [27]
    YILMAZ B, KOKLU S, BUYUKBAYRAM H, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis[J]. Afr Health Sci, 2015, 15(3): 714-718. DOI: 10.4314/ahs.v15i3.3.
    [28]
    PAIS R, FARTOUX L, GOUMARD C, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period[J]. Aliment Pharmacol Ther, 2017, 46(9): 856-863. DOI: 10.1111/apt.14261.
    [29]
    CHENG JY, WONG VW, TSE YK, et al. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B[J]. Hepatology, 2016, 64(5): 1507-1517. DOI: 10.1002/hep.28778.
    [30]
    CHEN Y, FAN C, CHEN Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study[J]. Oncotarget, 2017, 8(35): 58601-58610. DOI: 10.18632/oncotarget.17380.
    [31]
    PELEG N, ISSACHAR A, SNEH ARBIB O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load[J]. JHEP Rep, 2019, 1(1): 9-16. DOI: 10.1016/j.jhepr.2019.02.002.
    [32]
    CHAN AW, WONG GL, CHAN HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32(3): 667-676. DOI: 10.1111/jgh.13536.
    [33]
    DOGAN Z, FILIK L, ERGVL B, et al. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis[J]. Saudi J Gastroenterol, 2015, 21(6): 396-399. DOI: 10.4103/1319-3767.164186.
    [34]
    KIM DS, JEON MY, LEE HW, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir[J]. Clin Mol Hepatol, 2019, 25(3): 283-293. DOI: 10.3350/cmh.2018.0054.
    [35]
    ZHU LY, WANG YG, WEI LQ, et al. The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease[J]. Drug Des Devel Ther, 2016, 10: 2739-2744. DOI: 10.2147/DDDT.S114761.
    [36]
    CHEN YC, JENG WJ, HSU CW, et al. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study[J]. BMC Gastroenterol, 2020, 20(1): 146. DOI: 10.1186/s12876-020-01289-w.
    [37]
    LIANG H, LIU Y, JIANG X, et al. Impact of hepatic steatosis on the antiviral effects of PEG-IFNα-2a in patients with chronic hepatitis B and the associated mechanism[J]. Gastroenterol Res Pract, 2020, 2020: 1794769. DOI: 10.1155/2020/1794769.
    [38]
    ATEŞ F, YALN1Z M, ALAN S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B[J]. World J Gastroenterol, 2011, 17(40): 4517-4522. DOI: 10.3748/wjg.v17.i40.4517.
    [39]
    CEYLAN B, ARSLAN F, BAT1REL A, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir[J]. Turk J Gastroenterol, 2016, 27(1): 42-46. DOI: 10.5152/tjg.2015.150348.
    [40]
    CINDORUK M, KARAKAN T, UNAL S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection[J]. J Clin Gastroenterol, 2007, 41(5): 513-517. DOI: 10.1097/01.mcg.0000225586.78330.60.
    [41]
    SHI JP, LU L, QIANG JC, et al. Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B[J]. Chin J Hepatol, 2012, 20(4): 285-288. DOI: 10.3760/cma.j.issn.1007-3418.2012.04.012.

    施军平, 陆璐, 钱建成, 等. 肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J]. 中华肝脏病杂志, 2012, 20(4): 285-288. DOI: 10.3760/cma.j.issn.1007-3418.2012.04.012.
    [42]
    XU L, LI P, SHI QY, et al. Impact of liver steatosis on the curative effect of pegylated interferon-aipha-2a in patients with chronic hepatitis B[J]. Chin J Hepatol, 2015, 23(2): 99-102. DOI: 10.3760/cma.j.issn.1007-3418.2015.02.005

    徐亮, 李萍, 史琦玉, 等. 肝脂肪变对聚乙二醇干扰素α-2a治疗慢性乙型肝炎疗效的影响[J]. 中华肝脏病杂志, 2015, 23(2): 99-102. DOI: 10.3760/cma.j.issn.1007-3418.2015.02.005
    [43]
    JIN X, CHEN YP, YANG YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J]. PLoS One, 2012, 7(3): e34198. DOI: 10.1371/journal.pone.0034198.
    [44]
    CHEN MQ, WU JM, CHEN J, et al. The effect of non-alcoholic fatty liver disease on virologic response in patients with hepatitis B e antigen-positive chronic hepatitis B treated with nucleoside analogues[J]. Chin J Infect Dis, 2014, 32(3): 158-161. DOI: 10.3760/cma.j.issn.1000-6680.2014.03.007.

    陈梅琴, 吴金明, 陈娟, 等. 合并非酒精性脂肪性肝病对e抗原阳性慢性乙型肝炎患者核苷类似物抗病毒疗效的影响[J]. 中华传染病杂志, 2014, 32(3): 158-161. DOI: 10.3760/cma.j.issn.1000-6680.2014.03.007.
    [45]
    CHENG QG, WANG YJ, JI XY, et al. Efficacy of entecavir therapy for chronic hepatitis B patients; with non-alcoholic fatty liver disease[J]. Chin J Clin Infect Dis, 2015, 8(4): 348-350. DOI: 10.3760/cma.j.issn.1674-2397.2015.04.014.

    程乾刚, 王亚静, 季晓燕, 等. 非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎的影响[J]. 中华临床感染病杂志, 2015, 8(4): 348-350. DOI: 10.3760/cma.j.issn.1674-2397.2015.04.014.
    [46]
    GONG L, LIU J, WANG J, et al. Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B[J]. Transplant Proc, 2015, 47(10): 2886-2891. DOI: 10.1016/j.transproceed.2015.10.023.
    [47]
    SHAHEEN AA, ALMATTOOQ M, YAZDANFAR S, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers[J]. Aliment Pharmacol Ther, 2017, 46(6): 599-604. DOI: 10.1111/apt.14218.
    [48]
    SUZUKI K, SUDA G, YAMAMOTO Y, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection[J]. J Gastroenterol, 2021, 56(2): 168-180. DOI: 10.1007/s00535-020-01750-3.
    [49]
    HWANG EG, JUNG EA, YOO JJ, et al. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis[J]. Hepatol Int, 2023. DOI: 10.1007/s12072-023-10528-7. [Online ahead of print]
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (458) PDF downloads(140) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return